Skip to main content
Search
Search
Menu
Medicines
Human regulatory
Human regulatory
Overview
Research and development
Marketing authorisation
Post-authorisation
Herbal products
Veterinary regulatory
Veterinary regulatory
Overview
Research and development
Marketing authorisation
Post-authorisation
Committees
Committees
How the committees work
CHMP
CVMP
PRAC
COMP
HMPC
CAT
PDCO
Working parties and other groups
News & events
News & events
News and press releases
Events
What's new
Committee highlights
Therapeutic areas: latest updates
Publications
Press and social media
Open consultations
RSS feeds
Partners & networks
Partners & networks
EU partners
International activities
Patients and consumers
Healthcare professionals
Academia
Pharmaceutical industry
Networks
Health technology assessment bodies
About us
About us
What we do
Who we are
How we work
Annual reports and work programmes
History of EMA
Careers
Procurement
Support to research
Contact
Legal
Glossary
Search tips
FAQs
Brexit: UK withdrawal from EU
Medicines
Search
Download
What we publish and when
Medicines under evaluation
National registers
Medicines for use outside the EU
Fulltext search
Search
For help on how to get the results you want, see our
search tips
.
1 results
Remove all filters
Remove all filters
Medicine
Maximum residue limits
Remove Maximum residue limits filter
Summaries of opinion
Remove Summaries of opinion filter
Categories
Human
Remove Human filter
Medicine type
Generic
Remove Generic filter
Exceptional circumstances
Remove Exceptional circumstances filter
Sort by
Last updated date (new to old)
Last updated date (old to new)
Authorisation date
Medicine name
Active substance name
Relevance
Event date
Date of opinion
Sort
List item
Summary of opinion: Apixaban Accord
apixaban, opinion date: 28/05/2020, Positive, Last updated: 29/05/2020
